Theravance Biopharma, Inc. Share-based Payment Arrangement, Expense
Theravance Biopharma, Inc. (TBPH) reported Share-based Payment Arrangement, Expense of $5.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- Theravance Biopharma, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $5.99M, a 31.85% increase year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $4.50M, a 7.65% decline year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.48M, a 23.10% decline year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $4.58M, a 7.80% decline year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for fiscal 2025 was $18.48M, a 13.64% decline from fiscal 2024.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for fiscal 2024 was $21.39M, a 15.68% decline from fiscal 2023.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for fiscal 2023 was $25.37M, a 36.15% decline from fiscal 2022.
- Theravance Biopharma, Inc. share-based payment arrangement, expense for fiscal 2022 was $39.73M, a 35.98% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.99M 10-Q · filed 2026-08-11 | $10.49M 10-Q · filed 2026-08-11 | $14.97M derived: sum of 3 quarters · filed 2026-08-11 | $19.55M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $4.50M 10-Q · filed 2026-05-07 | $8.98M derived: sum of 2 quarters · filed 2026-05-07 | $13.56M derived: sum of 3 quarters · filed 2026-05-07 | $18.10M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $9.06M derived: sum of 2 quarters · filed 2026-03-23 | $13.60M derived: sum of 3 quarters · filed 2026-08-11 | $18.48M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $4.58M 10-Q · filed 2025-11-12 | $9.12M derived: sum of 2 quarters · filed 2026-08-11 | $14.00M 10-Q · filed 2025-11-12 | $19.82M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $4.54M 10-Q · filed 2026-08-11 | $9.42M 10-Q · filed 2026-08-11 | $15.25M derived: sum of 3 quarters · filed 2026-08-11 | $20.21M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $4.88M 10-Q · filed 2026-05-07 | $10.70M derived: sum of 2 quarters · filed 2026-05-07 | $15.67M derived: sum of 3 quarters · filed 2026-05-07 | $21.04M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.79M derived: sum of 2 quarters · filed 2026-03-23 | $16.16M derived: sum of 3 quarters · filed 2026-03-23 | $21.39M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $4.96M 10-Q · filed 2025-11-12 | $10.34M derived: sum of 2 quarters · filed 2025-11-12 | $15.57M 10-Q · filed 2025-11-12 | $21.39M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $5.38M 10-Q · filed 2025-08-13 | $10.60M 10-Q · filed 2025-08-13 | $16.43M derived: sum of 3 quarters · filed 2025-08-13 | $22.69M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $5.23M 10-Q · filed 2025-05-12 | $11.05M derived: sum of 2 quarters · filed 2025-05-12 | $17.32M derived: sum of 3 quarters · filed 2025-05-12 | $23.58M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $12.09M derived: sum of 2 quarters · filed 2025-03-07 | $18.35M derived: sum of 3 quarters · filed 2025-03-07 | $25.37M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $6.26M 10-Q · filed 2024-11-14 | $12.53M derived: sum of 2 quarters · filed 2024-11-14 | $19.55M 10-Q · filed 2024-11-14 | $26.50M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $6.26M 10-Q · filed 2024-08-08 | $13.29M 10-Q · filed 2024-08-08 | $20.23M derived: sum of 3 quarters · filed 2024-08-08 | $28.77M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $7.02M 10-Q · filed 2024-05-15 | $13.97M derived: sum of 2 quarters · filed 2024-05-15 | $22.50M derived: sum of 3 quarters · filed 2024-05-15 | $32.21M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $15.48M derived: sum of 2 quarters · filed 2024-03-01 | $25.19M derived: sum of 3 quarters · filed 2024-03-01 | $39.73M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $8.53M 10-Q · filed 2023-11-09 | $18.24M derived: sum of 2 quarters · filed 2023-11-09 | $32.78M 10-Q · filed 2023-11-09 | $49.70M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $9.71M 10-Q · filed 2023-08-09 | $24.25M 10-Q · filed 2023-08-09 | $41.17M derived: sum of 3 quarters · filed 2023-08-09 | $55.54M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $14.54M 10-Q · filed 2023-05-10 | $31.46M derived: sum of 2 quarters · filed 2023-05-10 | $45.83M derived: sum of 3 quarters · filed 2023-05-10 | $60.77M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $31.29M derived: sum of 2 quarters · filed 2023-03-01 | $46.23M derived: sum of 3 quarters · filed 2023-03-01 | $62.06M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $14.37M 10-Q · filed 2022-11-09 | $29.31M derived: sum of 2 quarters · filed 2022-11-09 | $45.14M 10-Q · filed 2022-11-09 | $60.69M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $14.94M 10-Q · filed 2022-08-08 | $30.77M 10-Q · filed 2022-08-08 | $30.77K 10-Q · filed 2021-08-05 | $46.32M derived: sum of 3 quarters · filed 2023-03-01 | $61.89M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $15.83M 10-Q · filed 2022-05-06 | $31.38M derived: sum of 2 quarters · filed 2023-03-01 | $46.95M derived: sum of 3 quarters · filed 2023-03-01 | $63.53M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $15.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $31.11M derived: sum of 2 quarters · filed 2023-03-01 | $47.70M derived: sum of 3 quarters · filed 2023-03-01 | $62.98M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $15.56M 10-Q · filed 2021-11-08 | $32.15M derived: sum of 2 quarters · filed 2021-11-08 | $47.42M 10-Q · filed 2021-11-08 | $71.34M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $16.59M 10-Q · filed 2021-08-05 | $31.86M 10-Q · filed 2021-08-05 | $55.77M derived: sum of 3 quarters · filed 2022-02-28 | $68.79M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $15.28M 10-Q · filed 2021-05-06 | $39.19M derived: sum of 2 quarters · filed 2022-02-28 | $52.21M derived: sum of 3 quarters · filed 2022-02-28 | $63.51M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $23.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $36.93M derived: sum of 2 quarters · filed 2022-02-28 | $48.23M derived: sum of 3 quarters · filed 2022-02-28 | $60.45M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $13.02M 10-Q · filed 2020-11-09 | $24.32M derived: sum of 2 quarters · filed 2020-11-09 | $36.54M 10-Q · filed 2020-11-09 | $48.25M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $11.30M 10-Q · filed 2020-08-10 | $23.52M 10-Q · filed 2020-08-10 | $35.23M derived: sum of 3 quarters · filed 2021-02-26 | $46.98M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | $12.22M 10-Q · filed 2020-05-08 | $23.93M derived: sum of 2 quarters · filed 2021-02-26 | $35.68M derived: sum of 3 quarters · filed 2021-02-26 | $49.53M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $23.46M derived: sum of 2 quarters · filed 2021-02-26 | $37.31M derived: sum of 3 quarters · filed 2021-02-26 | $51.31M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $11.75M 10-Q · filed 2019-11-08 | $25.60M derived: sum of 2 quarters · filed 2019-11-08 | $39.60M 10-Q · filed 2019-11-08 | $57.39M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $13.86M 10-Q · filed 2019-08-05 | $27.85M 10-Q · filed 2019-08-05 | $45.65M derived: sum of 3 quarters · filed 2020-02-27 | $56.33M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $14.00M 10-Q · filed 2019-05-10 | $31.79M derived: sum of 2 quarters · filed 2020-02-27 | $42.48M derived: sum of 3 quarters · filed 2020-02-27 | $52.87M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $17.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $28.48M derived: sum of 2 quarters · filed 2020-02-27 | $38.88M derived: sum of 3 quarters · filed 2020-02-27 | $49.15M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $10.69M 10-Q · filed 2018-11-08 | $21.08M derived: sum of 2 quarters · filed 2018-11-08 | $31.35M 10-Q · filed 2018-11-08 | $41.39M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $10.40M 10-Q · filed 2018-08-02 | $20.67M 10-Q · filed 2018-08-02 | $30.71M derived: sum of 3 quarters · filed 2019-02-28 | $40.60M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $10.27M 10-Q · filed 2018-05-09 | $20.31M derived: sum of 2 quarters · filed 2019-02-28 | $30.20M derived: sum of 3 quarters · filed 2019-02-28 | $40.11M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $19.93M derived: sum of 2 quarters · filed 2019-02-28 | $29.84M derived: sum of 3 quarters · filed 2019-02-28 | $41.17M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $9.89M 10-Q · filed 2017-11-08 | $19.80M derived: sum of 2 quarters · filed 2017-11-08 | $31.13M 10-Q · filed 2017-11-08 | $42.64M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $9.90M 10-Q · filed 2017-08-09 | $21.23M 10-Q · filed 2017-08-09 | $32.74M derived: sum of 3 quarters · filed 2018-02-28 | $45.00M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $11.33M 10-Q · filed 2017-05-10 | $22.84M derived: sum of 2 quarters · filed 2018-02-28 | $35.09M derived: sum of 3 quarters · filed 2018-02-28 | $49.75M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2015-12-31 | $11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $23.76M derived: sum of 2 quarters · filed 2018-02-28 | $38.42M derived: sum of 3 quarters · filed 2018-02-28 | $54.05M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $12.25M 10-Q · filed 2016-11-09 | $26.91M derived: sum of 2 quarters · filed 2016-11-09 | $42.54M 10-Q · filed 2016-11-09 | $56.96M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $14.66M 10-Q · filed 2016-08-09 | $30.29M 10-Q · filed 2016-08-09 | $44.71M derived: sum of 3 quarters · filed 2017-03-01 | $54.06M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $15.63M 10-Q · filed 2016-05-10 | $30.05M derived: sum of 2 quarters · filed 2017-03-01 | $39.40M derived: sum of 3 quarters · filed 2017-03-01 | $46.16M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $14.42M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $23.77M derived: sum of 2 quarters · filed 2017-03-01 | $30.53M derived: sum of 3 quarters · filed 2017-03-01 | $43.23M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $9.35M 10-Q · filed 2015-11-12 | $16.11M derived: sum of 2 quarters · filed 2015-11-12 | $28.81M 10-Q · filed 2015-11-12 | $33.97M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-06-30 | $6.76M 10-Q · filed 2015-08-13 | $19.46M 10-Q · filed 2015-08-13 | $24.62M derived: sum of 3 quarters · filed 2016-03-11 | $30.22M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-03-31 | $12.70M 10-Q · filed 2015-05-13 | $17.86M derived: sum of 2 quarters · filed 2016-03-11 | $23.45M derived: sum of 3 quarters · filed 2016-03-11 | $29.66M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2013-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $10.75M derived: sum of 2 quarters · filed 2016-03-11 | $16.96M derived: sum of 3 quarters · filed 2016-03-11 | $22.48M 10-K · filed 2016-03-11 | |
| 2013-09-30 | $5.59M 10-Q · filed 2014-11-12 | $11.80M derived: sum of 2 quarters · filed 2014-11-12 | $17.32M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $6.21M 10-Q · filed 2014-08-14 | $11.72M 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | $5.52M 10-Q · filed 2014-06-24 | ||||
| 2012-12-31 | $21.32M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |